Fed. Circ. Urged To Preserve Novartis' Bench Trial Loss
MSN Pharmaceuticals has pushed back against Novartis' efforts to save its case accusing the generic drugmaker of infringing a patent covering the blockbuster cardiovascular drug Entresto, telling the Federal Circuit that...To view the full article, register now.
Already a subscriber? Click here to view full article